LOS ANGELES, CA--(Marketwired - Feb 29, 2016) -  Cannabis Science, Inc. (OTC PINK: CBIS), a U.S. Company specializing in medicinal cannabis based formulations for formal drug development, continues to support top surgeon and CNN Medical Correspondent Dr. Sanjay Gupta for his historic and high profile work educating the U.S. and the world about the benefits of medical cannabis and support for the medical cannabis community.

Dr. Gupta is a media personality on health-related issues; he is best known as CNN's multiple Emmy Award-winning chief medical correspondent, hosting the network's weekend health program Sanjay Gupta, M.D., and making frequent appearances on their American Morning, Larry King Live and Anderson Cooper 360° programs.

Please click the following links for some of his advocacy work:


Some of his videos on marijuana topic

Dr. Gupta's Medical Marijuana call for Revolution



Business Insider provides a simple but powerful summary of the reasons for Dr. Gupta's impactful reporting: "9 Reasons Why Sanjay Gupta Changed His Mind About Marijuana".

A full copy of the article can be found here: http://finance.yahoo.com/news/9-reasons-sanjay-gupta-changed-170000967.html

Dr. Gupta produced CNN documentaries and ancillary articles on his findings concluding that medical cannabis is often safer and less toxic than prescription medication, not a surprising conclusion in a view of the long history of medical use by humanity, and with clear evidence that for some diseases and conditions, cannabis appears to be the only option for patients, many of whom are children.

Dr. Gupta also found that there are barriers, particularly legal, political, and governmental, not only to the use of medical cannabis but also to the basic research to study the plant as a medicine. Dr. Gupta, after his investigation, concluded that federal law is not based on science and the entire pharmaceutical and regulatory system is biased against research that would show medical cannabis as therapeutically beneficial to patients. The vast majority of recent studies (93%) are designed to find harm from medical cannabis and few (6%) to discover the benefits. Ironically, a significant majority (67%) of physicians surveyed would prescribe medical cannabis to patients if it were legal.

"Dr. Gupta has without doubt become a champion for patients in need of cannabis based medicines. His high profile and respected position has given him an incredible platform to change the focus of the medical cannabis debate. We at Cannabis Science are looking forward to supporting Dr. Gupta with providing state of art scientific data. Thanks to his commitment and the decades of work by countless advocates and patients, the pace of medical cannabis reform and the interest in providing science-based evidence has certainly accelerated," said Robert Kane, Director and CFO of Cannabis Science, Inc.

Dr. Gupta's groundbreaking CNN documentary based on balanced investigation may be viewed at the following link:

About Cannabis Science, Inc.

Cannabis Science, Inc., takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on skin cancers and neurological conditions.

Forward Looking Statements

This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as "anticipate," "seek," intend," "believe," "estimate," "expect," "project," "plan," or similar phrases may be deemed "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company's reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements.

Contact Information:

Cannabis Science, Inc.
Investor Relations
Teresa Misenheimer
Tel: 813.500.7332

Cannabis Science, Inc.
Mr. Raymond C. Dabney
Director, President & CEO, Co-Founder
Tel: 310.650.3788

Cannabis Science, Inc.
Mr. Robert Kane
Director & CFO
Tel: 1.888.889.0888